Peanut Allergy Treatment 2026: After Palforzia, What Comes Next?

April 1, 2026. That is the day Palforzia stopped taking new patients. No new enrollments. No exceptions. If your family was still weighing the decision, the window closed.

But here is what most allergy parents have not heard yet: the pipeline behind Palforzia is deeper than it has ever been. Three treatments could hit regulatory milestones before the end of 2026, and each one is designed to be easier to live with than what Palforzia required.

Why Palforzia Enrollment Closed and What It Means Right Now

Stallergenes Greer, the company that manufactures Palforzia, confirmed no new patients should begin treatment after April 1, 2026. The full discontinuation date is July 31, 2026. Patients already in the maintenance phase can continue through that deadline, and supplies are expected to hold.

According to Stallergenes Greer's discontinuation announcement, the company confirmed Palforzia's path from landmark FDA approval in 2020 to this exit. The official word: the discontinuation was not related to safety, quality, or whether the treatment worked. It worked. The commercial model just did not. In-clinic dosing, cold chain storage, a months-long up-dosing schedule, these were real barriers for real families. What comes next is designed to solve exactly those problems.

If your allergist was considering starting your child on Palforzia, that option is gone. Families who were waiting for the right moment missed it. That is the hard truth. And also: there is actually a lot coming.

The VIASKIN Peanut Patch: Closest to FDA Approval

The treatment closest to replacing Palforzia is not a pill or a powder. It is a small adhesive patch worn on the skin.

DBV Technologies is developing the VIASKIN Peanut patch, which delivers tiny amounts of peanut protein through the skin to build tolerance gradually. DBV has confirmed its first Biologics License Application (BLA) for children ages 4 to 7 is targeted for submission to the FDA by June 30, 2026. A second BLA for toddlers ages 1 to 3 is expected by the end of 2026 through an accelerated approval pathway.

The Phase 3 VITESSE trial gave strong results. According to DBV Technologies' VITESSE trial data, roughly 83% of treated children increased their tolerance to peanut protein by at least one dose level after 12 months. About 60% increased by at least two dose levels, compared to 23% in the placebo group. One finding that stood out: 24% of untreated children in the placebo group actually became more sensitized during the study period. Doing nothing is not neutral.

For families, the appeal of VIASKIN is simple: the patch is applied once daily at home. No clinic visits for dosing. No food to measure and swallow. The immune system does the work while the child goes about their day.

If the BLA filing happens on schedule and the FDA review follows a standard timeline, the earliest possible approval could come in 2027. That is not soon enough for families dealing with this today. It is closer than anything else in the pipeline, though.

The Peanut SLIT Tablet: A Daily Dissolve Under the Tongue

This is the one most allergy families have not heard about yet. And it may change more about long-term peanut allergy management than anything else in development.

ALK, a Danish pharmaceutical company, is developing a once-daily sublingual immunotherapy (SLIT) tablet for peanut allergy. The tablet goes under the tongue and dissolves. No needles, no patch, no clinic visits for dosing. Results from the Phase 1/2 ALLIANCE trial, presented at the 2026 AAAAI annual meeting, showed the tablet was well tolerated across children, adolescents, and adults.

The safety profile was notable. No systemic anaphylaxis occurred during the trial. No epinephrine was needed. Side effects were mild, mostly oral itching (88%), throat irritation (84%), and stomach discomfort. Children with a median age of 9 successfully tolerated the highest dose level tested.

Phase 2 is underway at 40 sites across the U.S. and Canada. Topline results are expected in mid-2026.

SLIT is not a new concept. Sublingual tablets already exist for grass pollen and dust mite allergies. ALK is adapting that same delivery method for food allergy. For families who found Palforzia's clinic-based protocol too burdensome, a daily tablet taken at home fills a real gap, something that feels as routine as a vitamin.

The SLIT tablet is still years from FDA approval. Phase 2 results will determine whether it moves into Phase 3. But the early signal is strong.

Other Treatments Worth Watching

Two more approaches are advancing through development and worth knowing about.

Remibrutinib (Rhapsido): Novartis is developing this oral medication, which works by blocking Bruton's tyrosine kinase (BTK), a protein involved in triggering allergic reactions. Unlike immunotherapy approaches that build tolerance to peanut specifically, remibrutinib aims to reduce the allergic response itself. Phase 3 trials are planned for later in 2026, according to Novartis's publicly available clinical development pipeline. If it works, this could potentially help across multiple food allergies, not just peanut.

Xolair (omalizumab): Xolair received FDA approval for food allergy in February 2024. It is a biologic injection that reduces the IgE antibodies responsible for allergic reactions. Unlike peanut-specific immunotherapy, it can raise reaction thresholds across multiple allergens simultaneously. Research presented at the 2025 AAAAI annual meeting showed it outperformed oral immunotherapy in multi-food allergy patients, with far fewer serious adverse events. For families managing more than one food allergy at once, it is worth asking your allergist about.

Because reaction severity can shift unpredictably from one exposure to the next, raising that threshold, even before a cure exists, is clinically meaningful. We covered why reactions can change so unpredictably from one exposure to the next if you want to understand the full picture.

What This Means for Your Family Today

If you spent any part of the last year thinking "we should really look into Palforzia," this news stings. A lot of families were in exactly that spot. Some were waiting until their child was a little older. Some until the clinic schedule cleared up. Some were still gathering the courage to start a 9-month dosing protocol with a kid who already has complicated feelings about food. That window is closed now, and that is genuinely hard.

The honest summary: nothing in this pipeline is available to prescribe tomorrow. VIASKIN is months from even filing with the FDA. The SLIT tablet is in mid-stage trials. Remibrutinib and Xolair address the problem from different angles but are not peanut-specific approvals yet.

What has genuinely changed is the range of approaches. When Palforzia was the only approved treatment, the choice was binary: try it or wait. Now the question is which type of treatment fits your family's life. A patch your child wears at home. A tablet dissolved under the tongue each morning. An injection that raises thresholds across multiple allergens. A pill that blocks the allergic pathway entirely. That is real progress, even when the timeline is slow.

If you are also tracking the latest neffy updates, worth noting: needle-free epinephrine just got more accessible for toddlers, with the FDA removing the age requirement in March 2026. The safety net is expanding on multiple fronts, even while the treatment side catches up.

Your allergist is the right person to talk through which of these to watch and whether any current off-label options make sense for your child now. The landscape is moving faster than most families realize. A proactive conversation helps you be ready when the first of these options reaches the market.

The peanut allergy treatment landscape in 2026 looks nothing like it did two years ago. Palforzia opened a door. Multiple treatments are now walking through it. The wait is real. So is the progress.

In the meantime, the daily food question does not pause for clinical trial timelines. Every snack your kid takes to school, every birthday party treat, every pantry staple still needs to clear a bar. NutFreeMarket exists to clear that bar before it gets to you. Every product comes from a dedicated nut-free facility, already verified. Browse nut-free snacks and pantry staples at NutFreeMarket.

Frequently Asked Questions

What peanut allergy treatments are available after Palforzia in 2026?

No FDA-approved peanut-specific oral immunotherapy is currently available after Palforzia's enrollment closure on April 1, 2026. The closest treatments in the pipeline are the VIASKIN peanut patch (BLA filing targeted by June 30, 2026), a peanut SLIT tablet in Phase 2 trials, remibrutinib with Phase 3 planned for late 2026, and Xolair for multi-allergen management. Your allergist may also discuss physician-supervised protocols using commercial peanut flour as an interim approach.

When will the VIASKIN peanut patch be available?

DBV Technologies has targeted a BLA submission to the FDA by June 30, 2026 for children ages 4 to 7. A second submission for toddlers ages 1 to 3 is expected by end of 2026. If the FDA review follows a standard timeline, the earliest possible approval could come in 2027.

What is the peanut SLIT tablet?

It is a once-daily sublingual immunotherapy tablet being developed by ALK. The tablet is placed under the tongue and dissolves, delivering small amounts of peanut protein to build tolerance. Early trial results showed it was well tolerated with no systemic anaphylaxis events. Phase 2 results are expected in mid-2026.

Can my child still use Palforzia if they already started?

Yes. Patients currently in the maintenance phase can continue through the July 31, 2026 discontinuation date. Supplies are expected to remain available through that window. After July 31, your allergist can discuss transitioning to physician-supervised protocols.

Should I talk to my allergist about these new treatments?

Yes. Even though these treatments are not yet approved, your allergist can help you understand which options to watch, whether any off-label approaches are appropriate for your child, and how to prepare as new treatments become available.